Research programme: lactic acid bacteria S-PT84 - Daiichi Asubio Pharma

Drug Profile

Research programme: lactic acid bacteria S-PT84 - Daiichi Asubio Pharma

Alternative Names: Lactobacillus pentosus S-PT84; Lactic acid bacteria S-PT84 research programme - Daiichi Suntory Pharma

Latest Information Update: 11 Apr 2007

Price : $50

At a glance

  • Originator Daiichi Sankyo Company
  • Class
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.


Highest Development Phases

  • No development reported Bacterial infections

Most Recent Events

  • 11 Apr 2007 No development reported - Preclinical for Bacterial infections in Japan (unspecified route)
  • 16 Sep 2005 Daiichi Suntory Pharma has been acquired by Daiichi Pharmaceutical
  • 14 Dec 2004 Preclinical trials in Bacterial infections in Japan (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top